The study involved two major activities in estimating the current market size of the Human Microbiome Research Spending Market. Exhaustive research was conducted to collect information on the market as well as its peer and parent markets.

The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation were used to estimate the market size of segments and subsegments.

Human Microbiome Market is expected to grow from USD 942 million in 2024 to USD 1,731 million by 2027, at a CAGR of 22.5% during the forecast period.

Microbiomes are responsible for a wide variety of metabolic and developmental processes—from food digestion to vitamin synthesis and even brain function. They also play a major role in human conditions, such as obesity and inflammatory bowel disease.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=37621904

Market Size Estimation:

Both top-down and bottom-up approaches have been used to estimate and validate the size of the human microbiome market and to estimate the size of various submarkets. In this report, the global market size for human microbiome was calculated using the epidemiology approach.

# Key indications were identified for which microbiome therapy clinical trials are underway.

# The therapy market pertaining to each indication was derived based on secondary and primary research.

# Microbiome therapeutics are likely to be adopted by a set of patients who show side-effects for existing therapies. Therefore, the percentage of the patient population showing some side-effects with existing therapies were identified. This percentage was then applied to the total therapy market to derive the total addressable market for human microbiome.

# To calculate the total market for microbiome therapy, the adoption rate for microbiome therapies was applied to the total addressable market.

# This approach was then validated from primary experts from both demand and supply-side.

Europe to account for the largest share of the human microbiome market in 2022

On the basis of region, the global Human Microbiome Research Spending Market is segmented into four major geographies— North America, Europe, the Asia Pacific, and the Rest of the World (RoW). Europe is expected to account for the largest share of the global human microbiome market in 2022. The large share of this regional segment is mainly due to the high research activity in this region.

Recent Developments:

# In 2019, Seres collaborated with AstraZeneca to get a better understanding of the microbiome in augmenting the efficacy of cancer immunotherapy, including potential synergy with AstraZeneca compounds.

# In 2018, Enterome entered into a co-development and co-promotion agreement with Takeda for its investigational drug candidate EB8018. This drug is used in patients with Crohn's disease and has the potential to expand its use to other gastrointestinal (GI) disorders and liver diseases.

# In 2016, 4D Pharma acquired the production assets of Instituto Biomar to expand its clinical and production capabilities of live biotherapeutics.

Global Leaders:

The major players in the human microbiome market include Enterome Bioscience (France), 4D Pharma (UK), and Seres Therapeutics (US).

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=37621904

Various growth strategies have been adopted by these players, such as product launches, agreements, and acquisitions to increase their presence in the global human microbiome market.

Key questions addressed by the report:

# Who are the major market players in the Human Microbiome Research Spending Market?
# What are the regional growth trends and the largest revenue-generating regions for the market?
# What are the major drivers and challenges in the market?
# What are the major product segments in the market?
# What are the major technologies used in the human microbiome research spending market?

About MarketsandMarkets™:

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]